Speaking of low-priced bios, ARGS -73%. Argos Therapeutics (ARGS) shares plunged 72% in pre-market trade Wednesday, coming off a trading halt, after the company said the independent data monitoring committee recommended a trial for its metastatic renal cell carcinoma treatment be discontinued.
Register for free to join our community of investors and share your ideas. You will also get access to streaming quotes, interactive charts, trades, portfolio, live options flow and more tools.